| Literature DB >> 35622323 |
Christiane Pott1, Michaela Kotrova2, Nikos Darzentas2, Monika Brüggemann2, Mouhamad Khouja2.
Abstract
Liquid biopsy is a novel diagnostic approach at first developed to characterize the molecular profile of solid tumors by analyzing body fluids. For cancer patients, it represents a noninvasive way to monitor the status of the solid tumor with respect to representative biomarkers. There is growing interest in the utilization of circulating tumor DNA (ctDNA) analysis also in the diagnostic and prognostic fields of lymphomas. Clonal immunoglobulin (IG) gene rearrangements are fingerprints of the respective lymphoid malignancy and thus are highly suited as specific molecular targets for minimal residual disease (MRD) detection. Tracing of the clonal IG rearrangement patterns in ctDNA pool during treatment can be used for MRD assessment in B-cell lymphomas. Here, we describe a reproducible next-generation sequencing assay to identify and characterize clonal IG gene rearrangements for MRD detection in cell-free DNA.Entities:
Keywords: Cell-free DNA; Digital droplet PCR; Immunoglobulin rearrangements; Liquid biopsy; Minimal residual disease; Next-generation sequencing; Plasma; Therapy monitoring
Mesh：
Substances：
Year: 2022 PMID： 35622323 DOI： 10.1007/978-1-0716-2115-8_7
Source DB: PubMed Journal: Methods Mol Biol ISSN： 1064-3745